Afatinib
- Generic Name
- Afatinib
- Brand Names
- Gilotrif, Giotrif
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25ClFN5O3
- CAS Number
- 850140-72-6
- Unique Ingredient Identifier
- 41UD74L59M
- Background
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif . For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by ...
- Indication
Afatinib is a kinase inhibitor indicated as monotherapy for the first-line treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test , and (b) adult pa...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory, metastatic squamous cell Non-small cell lung cancer
- Associated Therapies
- -
Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05517330
- Locations
- 🇨🇳
Xingchen Peng, Chengdu, Sichuan, China
Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05516589
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Pilot Trial for Treatment of Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT05432518
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05267288
- Locations
- 🇨🇳
Qingdao Central Hospital, Qingdao, China
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05215548
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳National Taiwan University Cancer Center, Taipei, Taiwan
JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Peking University
- Target Recruit Count
- 50
- Registration Number
- NCT05164848
- Locations
- 🇨🇳
Henan Cancer Hospital, Henan, Henan, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Anhui Provincial Hospital, Hefei, Hefei, China
Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)
- Conditions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05107193
Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Seoul St. Mary's Hospital
- Target Recruit Count
- 737
- Registration Number
- NCT04930133
- Locations
- 🇰🇷
Jin Hyoung Kang, Seoul, Korea, Republic of
Observational Study of Afatinib 30 mg Daily
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 69
- Registration Number
- NCT04909073
- Locations
- 🇸🇬
Nationa University Hospital, Singapore, Singapore
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Peking University
- Target Recruit Count
- 43
- Registration Number
- NCT04880811
- Locations
- 🇨🇳
Peking University Cancer Hospital and Institute, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.